Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT.

Da Silva Figueiredo Celestino Gomes P, Chauvot De Beauchêne I, Panel N, Lopez S, De Sepulveda P, Geraldo Pascutti P, Solary E, Tchertanov L.

PLoS One. 2016 Jul 28;11(7):e0160165. doi: 10.1371/journal.pone.0160165. eCollection 2016 Jul 28.

2.

New Developments in Chronic Myeloid Leukemia: Implications for Therapy.

Tabarestani S, Movafagh A.

Iran J Cancer Prev. 2016 Feb 22;9(1):e3961. doi: 10.17795/ijcp-3961. eCollection 2016 Feb 22. Review.

3.

c-Abl Tyrosine Kinase Adopts Multiple Active Conformational States in Solution.

Badger J, Grover P, Shi H, Panjarian SB, Engen JR, Smithgall TE, Makowski L.

Biochemistry. 2016 Jun 14;55(23):3251-60. doi: 10.1021/acs.biochem.6b00202. Epub 2016 Jun 3.

4.

A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors.

Wei Y, Poon DC, Fei R, Lam AS, Au-Yeung SC, To KK.

Sci Rep. 2016 May 6;6:25363. doi: 10.1038/srep25363.

5.

BCR: a new target in resistance mediated by BCR/ABL-315I?

Haberbosch I, Rafiei A, Oancea C, Ottmann GO, Ruthardt M, Mian AA.

Genes Cancer. 2016 Jan;7(1-2):36-46.

6.

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

Zhao B, Sedlak JC, Srinivas R, Creixell P, Pritchard JR, Tidor B, Lauffenburger DA, Hemann MT.

Cell. 2016 Mar 24;165(1):234-46. doi: 10.1016/j.cell.2016.01.045. Epub 2016 Feb 25.

7.

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

Zabriskie MS, Eide CA, Yan D, Vellore NA, Pomicter AD, Savage SL, Druker BJ, Deininger MW, O'Hare T.

Leukemia. 2016 Jun;30(6):1418-21. doi: 10.1038/leu.2015.318. Epub 2015 Nov 19. No abstract available.

8.

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.

Hughes TP, Saglio G, Quintás-Cardama A, Mauro MJ, Kim DW, Lipton JH, Bradley-Garelik MB, Ukropec J, Hochhaus A.

Leukemia. 2015 Sep;29(9):1832-8. doi: 10.1038/leu.2015.168. Epub 2015 Jun 29.

9.

Constitutive Activity in an Ancestral Form of Abl Tyrosine Kinase.

Aleem SU, Craddock BP, Miller WT.

PLoS One. 2015 Jun 19;10(6):e0131062. doi: 10.1371/journal.pone.0131062. eCollection 2015 Jun 19.

10.

Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.

de Oliveira GA, Rangel LP, Costa DC, Silva JL.

Front Oncol. 2015 Apr 29;5:97. doi: 10.3389/fonc.2015.00097. eCollection 2015 Apr 29. Review.

11.

The C2 Domain and Altered ATP-Binding Loop Phosphorylation at Ser³⁵⁹ Mediate the Redox-Dependent Increase in Protein Kinase C-δ Activity.

Gong J, Yao Y, Zhang P, Udayasuryan B, Komissarova EV, Chen J, Sivaramakrishnan S, Van Eyk JE, Steinberg SF.

Mol Cell Biol. 2015 May;35(10):1727-40. doi: 10.1128/MCB.01436-14. Epub 2015 Mar 9.

12.

Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors.

Aggoune D, Tosca L, Sorel N, Bonnet ML, Dkhissi F, Tachdjian G, Bennaceur-Griscelli A, Chomel JC, Turhan AG.

Oncoscience. 2014 Jan 30;1(1):57-68. eCollection 2014 Jan 30.

13.

Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.

Appelmann I, Rillahan CD, de Stanchina E, Carbonetti G, Chen C, Lowe SW, Sherr CJ.

Blood. 2015 Feb 26;125(9):1444-51. doi: 10.1182/blood-2014-09-601062. Epub 2014 Dec 12.

14.

Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.

Eiring AM, Deininger MW.

Genome Biol. 2014 Sep 17;15(9):461. doi: 10.1186/s13059-014-0461-8. Review.

15.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T.

Cancer Cell. 2014 Sep 8;26(3):428-42. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14.

16.

Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.

Jabbour EJ, Cortes JE, Kantarjian HM.

Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):515-29. doi: 10.1016/j.clml.2013.03.018. Epub 2013 Jul 26. Review.

17.

β-Turn sequences promote stability of peptide substrates for kinases within the cytosolic environment.

Yang S, Proctor A, Cline LL, Houston KM, Waters ML, Allbritton NL.

Analyst. 2013 Aug 7;138(15):4305-11. doi: 10.1039/c3an00874f. Epub 2013 Jun 20.

18.

Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.

Kurokawa M, Ito T, Yang CS, Zhao C, Macintyre AN, Rizzieri DA, Rathmell JC, Deininger MW, Reya T, Kornbluth S.

Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2300-5. doi: 10.1073/pnas.1206551110. Epub 2013 Jan 16.

19.

Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors.

Panjarian S, Iacob RE, Chen S, Wales TE, Engen JR, Smithgall TE.

J Biol Chem. 2013 Mar 1;288(9):6116-29. doi: 10.1074/jbc.M112.431312. Epub 2013 Jan 9.

20.

PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells.

Wu N, Kurosu T, Oshikawa G, Nagao T, Miura O.

Int J Oncol. 2013 Feb;42(2):419-28. doi: 10.3892/ijo.2012.1729. Epub 2012 Dec 6.

Supplemental Content

Support Center